BLUEBIRD BIO INC's ticker is BLUE and the CUSIP is 09609G100. A total of 155 filers reported holding BLUEBIRD BIO INC in Q2 2022. The put-call ratio across all filers is 1.50 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $77,359 | -13.9% | 25,447 | -6.8% | 0.00% | – |
Q2 2023 | $89,847 | +2.0% | 27,309 | -1.4% | 0.00% | – |
Q1 2023 | $88,115 | -59.9% | 27,709 | -12.7% | 0.00% | – |
Q4 2022 | $219,579 | -3.3% | 31,731 | -11.4% | 0.00% | -100.0% |
Q3 2022 | $227,000 | +63.3% | 35,817 | +6.4% | 0.00% | – |
Q2 2022 | $139,000 | -82.6% | 33,661 | +268.6% | 0.00% | -100.0% |
Q4 2019 | $801,000 | +107.0% | 9,132 | +116.6% | 0.00% | +200.0% |
Q3 2019 | $387,000 | -29.8% | 4,217 | -2.6% | 0.00% | -50.0% |
Q2 2019 | $551,000 | +43.1% | 4,328 | +76.7% | 0.00% | 0.0% |
Q1 2019 | $385,000 | +80.8% | 2,450 | +14.2% | 0.00% | +100.0% |
Q4 2018 | $213,000 | -12.0% | 2,146 | +29.5% | 0.00% | 0.0% |
Q3 2018 | $242,000 | -31.6% | 1,657 | -26.5% | 0.00% | -50.0% |
Q2 2018 | $354,000 | -29.6% | 2,253 | -23.4% | 0.00% | -33.3% |
Q1 2018 | $503,000 | -9.4% | 2,943 | -5.6% | 0.00% | 0.0% |
Q4 2017 | $555,000 | +83.8% | 3,117 | +41.6% | 0.00% | +50.0% |
Q3 2017 | $302,000 | +43.1% | 2,202 | +9.4% | 0.00% | +100.0% |
Q2 2017 | $211,000 | – | 2,012 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TANG CAPITAL MANAGEMENT LLC | 6,335,528 | $40,104,000 | 4.92% |
qPULA Trading Management LP | 14,344 | $91,000 | 0.80% |
Frazier Life Sciences Management, L.P. | 1,440,757 | $9,120,000 | 0.70% |
Ikarian Capital, LLC | 462,628 | $2,928,000 | 0.58% |
Birchview Capital, LP | 98,000 | $620,000 | 0.44% |
HealthCor Management, L.P. | 455,000 | $2,880,000 | 0.36% |
Financial Advocates Investment Management | 45,071 | $3,538,000 | 0.29% |
PDT Partners, LLC | 262,767 | $1,663,000 | 0.25% |
Monaco Asset Management SAM | 80,000 | $506,000 | 0.19% |
Summit X, LLC | 103,424 | $651,000 | 0.19% |